| Pharmaceutical Information |
| Drug Name |
Paraldehyde |
| Drug ID |
BADD_D01672 |
| Description |
Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo effect. |
| Indications and Usage |
Paraldehyde was used historically as a sedative and hypnotic [A19735]. It has been used in the treatment of seizures as an anticonvulsant [A19736]. |
| Marketing Status |
approved; investigational |
| ATC Code |
N05CC05 |
| DrugBank ID |
DB09117
|
| KEGG ID |
D00705
|
| MeSH ID |
D010242
|
| PubChem ID |
31264
|
| TTD Drug ID |
D0P9EA
|
| NDC Product Code |
Not Available |
| UNII |
S6M3YBG8QA
|
| Synonyms |
Paraldehyde |
|
| Chemical Information |
| Molecular Formula |
C6H12O3 |
| CAS Registry Number |
123-63-7 |
| SMILES |
CC1OC(OC(O1)C)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
